2026 ACHONDROPLASIA & SKELETAL DYSPLASIA RESEARCH CONFERENCE • ORLANDO, FL
SOURCE: Investors.AscendisPharma.com (June 2, 2025) – Once-weekly TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – Multiple benefits beyond linear growth were observed compared…
SOURCE: Investors.AscendisPharma.com — Data demonstrated multiple clinical benefits beyond linear growth — NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with achondroplasia, with up to three years…
SOURCE Results from Ongoing CANOPY Clinical Program for VOXZOGO Showcase Impact of C-Type Natriuretic Peptide (CNP) as Master Regulator of Growth-Related Development Across Multiple Genetic Skeletal Conditions New Data Highlight…
– TransCon CNP demonstrated AGV superior to placebo with LS mean treatment difference of 1.49 cm/year at Week 52 (p<0.0001) – For children aged 5-11 years TransCon CNP demonstrated…
SOURCE – Ascendis Pharma A/S • Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal…
Ozono, K., Kubota, T., & Michigami, T. (2024). Promising horizons in achondroplasia along with the development of new drugs. Endocrine journal, 10.1507/endocrj.EJ24-0109. Advance online publication. https://doi.org/10.1507/endocrj.EJ24-0109 AFFILIATIONS ABSTRACT Achondroplasia (ACH) is…
